DUBLIN--(BUSINESS WIRE)--The "2018-2022 Europe Tumor Marker Diagnostics Market: France, Germany, Italy, Spain, UK - Market Share Analysis, Country Segment Forecasts, Competitive Intelligence, Instrumentation Review, Technology Trends, Opportunities for Suppliers" report has been added to ResearchAndMarkets.com's offering.
This five-country report contains 820 pages, 320 tables, and presents analysis of the major business opportunities emerging in the cancer diagnostics market during the next five years. The report examines trends in major European countries (France, Germany, Italy, Spain, UK); reviews current and emerging tests; analyzes potential applications of various diagnostic technologies; forecasts sales of major tumor markers by country and market segment; profiles leading market players and potential entrants; and suggests alternative business expansion strategies for suppliers.
The cancer diagnostics market is on the verge of explosion, as the researchers approach major technological breakthroughs in tumor diagnosis and therapy, discover new specific antigens, and unlock the mystery of the genetic basis of the disease. During the next five years, the European cancer diagnostics market is promising to be an exciting, dynamic and rapidly expanding field. Anticipated technological breakthroughs will create numerous opportunities for determining genetic predisposition, detecting specific tumors, and monitoring biological response to cancer therapy. The rise in geriatric population will further compound the growing demand for malignancy assays and the rapid market expansion.
Cancer Diagnostic Tests
ACTH, AFP, Beta-2 Microglobulin, CA 15-3/27.29, CA 19-9, CA 125, Calcitonin, Cathepsin, CEA, Chromogranin, Colon-Specific Antigen, Cytokeratins, Estrogen Receptor, Ferritin, Gastrin, HCG, Insulin, Interferons, Interleukins, Lymphocyte Subtyping, Neuron-Specific Enolase, Nucleolar, Occult Blood, Oncogenes, Pancreatic Oncofetal Antigen, Pap Smear, Parathyroid Hormone, Progesterone Receptor, Prostatic Acid Phosphatase, Prostatic Specific Antigen, S-100 Protein, Serotonin, Sialic Acid, Squamous Cell Carcinoma Ag, TDT, Thymidine Kinase, Thyroglobulin, Tissue Polypeptide Antigen, and others.
Market Segmentation Analysis
Sales and market shares of major suppliers, by individual cancer diagnostic test and country.
Five-year test volume and sales forecasts for major cancer diagnostic tests by country and market segment, including:
- Hospitals
- Commercial/Private Laboratories
- Physician Offices/Group Practices
Comprehensive market segmentation analysis, including review of the market dynamics, structure, size, growth and major suppliers by country.
Cancer statistics, etiology and recent developments in five major European countries.
Current and Emerging Products
Review of over 200 current and emerging cancer diagnostic tests, including:
- Biochemical Markers
- Oncogenes
- Growth Factors
- Hormones
- Colony Stimulating Factors
- Lymphokines
- Immunohistochemical Stains
- Others
Analysis of major immunoassay analyzers used for cancer diagnostic testing, including their operating characteristics, features and selling prices.
Technology Review
Assessment of monoclonal antibodies, immunoassays, DNA probes, biochips/microarrays, chromosome analysis, IT, artificial intelligence, flow cytometry, biosensors, and other technologies and their potential applications for cancer diagnostic testing.
Review of competing/complementing technologies, including CT, MRI, NMR, PET and photonics spectroscopy.
Extensive listings of over 500 companies, universities and research centers developing new cancer diagnostic tests and detection technologies.
Competitive Assessments
Strategic assessments ofmajor suppliers and start-up firms developing innovative technologies and products, including their sales, product portfolios, marketing tactics, collaborative arrangements, and new products in R&D.
Business Opportunities and Strategic Recommendations
Specific new product development opportunities with potentially significant market appeal during the next five years.
Design criteria for new products.
Alternative market penetration strategies.
Potential market entry barriers and risks.
Companies Mentioned
- Abbott
- AdnaGen/Alere
- Agilent Technologies
- Applied Gene Technologies
- Arca Biopharma
- Beckman Coulter/Danaher
- Becton Dickinson
- Biomedical Diagnostics/Theradiag
- bioMerieux
- Bio-Rad
- Correlogic Systems/Vermillion
- Decode Genetics
- Diadexus
- Diagnocure
- Enterix/Clinical Genomics
- Enzo Biochem
- Exact Sciences
- Fujirebio
- Hologic/Gen-Probe
- Myriad Genetics
- OncoLab
- Ortho-Clinical Diagnostics
- Panacea Pharmaceuticals
- Polartechnics
- Polymedco
- PreMD
- Qiagen
- Quest Diagnostics
- Radient Pharmaceuticals
- Roche
- Siemens Healthcare
- Targeted Diagnostics & Therapeutics
- Wako Pure Chemicals
- Wallac/PE
- Zila
For more information about this report visit https://www.researchandmarkets.com/research/8t3gg4/2018_european?w=4
